

or a pharmaceutically acceptable salt thereof, wherein:

- L_1 is a bond;
- L_2 is a C_1 - C_6 saturated alkylene, or C_1 - C_6 heteroalkylene;
- R_1 is $-C(=O)OR_8$;
- R_2 is hydrogen, $-OR_9$, $-N(R_9)_2$, $-C(=O)R_9$, C_1 - C_6 saturated alkyl, C_3 - C_8 cycloalkyl, C_1 - C_6 haloalkyl, or optionally substituted heterocycloalkyl;
- R_3 is hydrogen, halogen, C_1 - C_6 saturated alkyl, or C_1 - C_6 haloalkyl;
- R_4 is aryl or heteroaryl; wherein aryl and heteroaryl are substituted with at least one R_{11} ;
- each R_5 is independently halogen, C_1 - C_6 saturated alkyl, or C_1 - C_6 haloalkyl;
- R_8 is C_1 - C_6 saturated alkyl, C_1 - C_6 heteroalkyl, $-C_1$ - C_6 saturated alkyl-aryl, aryl, or heteroaryl;
- R_9 is hydrogen, C_1 - C_6 saturated alkyl, C_1 - C_6 heteroalkyl, $-C_1$ - C_6 saturated alkyl-aryl, aryl, or heteroaryl;
- each R_{10} are each independently hydrogen, C_1 - C_6 saturated alkyl, C_1 - C_6 heteroalkyl, $-C_1$ - C_6 saturated alkyl-aryl, aryl, or heteroaryl;
- each R_{11} is independently halogen, nitro, $-OR_{10}$, $-N(R_{10})_2$, $-CN$, $-C(=O)R_{10}$, $-C(=O)OR_{10}$, $-C(=O)N(R_{10})_2$, $-NR_{10}C(=O)R_{10}$, $-NR_{10}SO_2R_{10}$, $-SOR_{10}$, $-SO_2R_{10}$, $-SO_2N(R_{10})_2$, $-C(=O)OCH_2SCH_3$, optionally substituted C_1 - C_6 saturated alkyl, optionally substituted C_3 - C_8 cycloalkyl, optionally substituted C_1 - C_6 haloalkyl, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted $-C_1$ - C_6 saturated alkyl-aryl, optionally substituted aryl, or optionally substituted heteroaryl; and
- n is 0-4.


Also provided is a compound of Formula (III):

n is 0-4;

or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

5

In another aspect, there is provided a compound of Formula (IV):



wherein:

10 R_1 is C_1 - C_6 saturated alkyl or C_2 - C_6 alkenyl, wherein said C_1 - C_6 saturated alkyl is optionally substituted by 1, 2, 3, or 4 substituents independently selected from hydroxy, C_1 - C_4 alkoxy, and C_1 - C_4 haloalkoxy;

L_2 is a C_1 - C_6 saturated alkylene;

R_2 is $C(=O)OR_9$;

15 R_3 is hydrogen or C_1 - C_6 saturated alkyl;

R_4 is phenyl substituted with at least one R_{11} ;

each R_9 is independently C_1 - C_6 saturated alkyl;

each R_{10} is independently hydrogen or C_1 - C_6 saturated alkyl; and


each R_{11} is independently halogen, nitro, $-OR_{10}$, $-N(R_{10})_2$, $-CN$, $-C(=O)R_{10}$, -

20 $C(=O)OR_{10}$, $-C(=O)N(R_{10})_2$, $-NR_{10}C(=O)R_{10}$, $-NR_{10}SO_2R_{10}$, $-SOR_{10}$, $-SO_2R_{10}$, $-SO_2N(R_{10})_2$, -
 $C(=O)OCH_2SCH_3$, C_1 - C_6 saturated alkyl, or C_1 - C_6 halosaturated alkyl, wherein said C_1 - C_6
saturated alkyl is optionally substituted by 1, 2, 3, or 4 substituents independently selected
from cyano, hydroxy, C_1 - C_4 alkoxy, C_1 - C_4 haloalkoxy, amino, C_1 - C_4 saturated alkylamino,
and $di(C_1$ - C_4 saturated alkyl)amino;

25 provided that at least one R_{11} is $-NR_{10}C(=O)R_{10}$, $-NR_{10}SO_2R_{10}$, $-SOR_{10}$, $-SO_2R_{10}$, or -
 $SO_2N(R_{10})_2$.

Disclosed is a compound of Formula (IV):

In another aspect there is provided a compound of Formula (IA):



wherein:

L_1 and L_2 are each independently a bond, C_1 - C_6 saturated alkylene, or C_1 - C_6 heteroalkylene; wherein C_1 - C_6 saturated alkylene and C_1 - C_6 heteroalkylene are optionally substituted with at least one R_7 ;

R_1 is halogen, $-CF_3$, $-OR_8$, $-N(R_8)_2$, $-C(=O)R_8$, $-C(=O)OR_8$, $-C(=O)N(R_8)_2$, $-C(=N-OH)R_8$, $-C(=S)N(R_8)_2$, C_1 - C_6 saturated alkyl, C_1 - C_6 heteroalkyl, or optionally substituted C_2 - C_7 heterocycloalkyl;

R_2 is $-C(=O)OR_9$;

R_3 is hydrogen, halogen, C_1 - C_6 saturated alkyl, or C_1 - C_6 haloalkyl;

each R_7 is independently C_1 - C_6 saturated alkyl, C_3 - C_8 cycloalkyl, C_1 - C_6 haloalkyl, C_1 - C_6 heteroalkyl, $-C_1$ - C_6 saturated alkyl-aryl, optionally substituted aryl, or optionally substituted heteroaryl;

each R_9 is independently C_1 - C_6 saturated alkyl, C_1 - C_6 heteroalkyl, $-C_1$ - C_6 saturated alkyl-aryl, aryl, or heteroaryl;


each R_8 and each R_{10} are each independently hydrogen, C_1 - C_6 saturated alkyl, C_1 - C_6 heteroalkyl, $-C_1$ - C_6 saturated alkyl-aryl, aryl, or heteroaryl;

m is 0 or 1;

R_{11a} is $-NR_{10}SO_2R_{10}$, $-SOR_{10}$, $-SO_2R_{10}$, or $-SO_2N(R_{10})_2$;

each R_{11} is independently halogen, nitro, $-OR_{10}$, $-N(R_{10})_2$, $-CN$, $-C(=O)R_{10}$, $-C(=O)OR_{10}$, $-C(=O)N(R_{10})_2$, $-NR_{10}C(=O)R_{10}$, $-NR_{10}SO_2R_{10}$, $-SOR_{10}$, $-SO_2R_{10}$, $-SO_2N(R_{10})_2$, $-C(=O)OCH_2SCH_3$, optionally substituted C_1 - C_6 saturated alkyl, optionally substituted C_3 - C_8 cycloalkyl, optionally substituted C_1 - C_6 haloalkyl, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted $-C_1$ - C_6 saturated alkyl-aryl, optionally substituted aryl, or optionally substituted heteroaryl; or a pharmaceutically acceptable salt thereof.

In another aspect, there is provided a compound of Formula (II):



8b

or a pharmaceutically acceptable salt thereof, wherein:

X is $-C(R_6)=C(R_6)-$;

L₁ is a bond, C₁-C₆ saturated alkylene, or C₁-C₆heteroalkylene; wherein C₁-C₆ saturated alkylene and C₁-C₆heteroalkylene are optionally substituted with at least one R₇;

L₂ is a C₁-C₆ saturated alkylene or C₁-C₆heteroalkylene;

R₁ is $-C(=O)OR_8$;

R₂ is hydrogen, $-OR_9$, $-N(R_9)_2$, $-C(=O)R_9$, $-C(=O)N(R_9)_2$, $-C(=N-OH)R_9$, $-C(=S)N(R_9)_2$, C₁-C₆ saturated alkyl, C₃-C₈cycloalkyl, C₁-C₆haloalkyl, C₁-C₆heteroalkyl, or optionally substituted heterocycloalkyl;

R₃ is hydrogen, halogen, C₁-C₆ saturated alkyl, or C₁-C₆haloalkyl;

R₄ is aryl or heteroaryl; wherein aryl and heteroaryl are substituted with at least one R₁₁;

each R₅ is independently halogen, C₁-C₆ saturated alkyl, or C₁-C₆haloalkyl;

each R₆ is independently hydrogen, halogen, C₁-C₆ saturated alkyl, or C₁-C₆haloalkyl;

each R₇ is independently C₁-C₆ saturated alkyl, C₃-C₈cycloalkyl, C₁-C₆haloalkyl, C₁-C₆heteroalkyl, $-C_1-C_6$ saturated alkyl-aryl, optionally substituted aryl, or optionally substituted heteroaryl;

each R₈ is independently C₁-C₆saturated alkyl, C₁-C₆heteroalkyl, $-C_1-C_6$ saturated alkyl-aryl, aryl, or heteroaryl;

each R₉ and each R₁₀ are each independently hydrogen, C₁-C₆ saturated alkyl, C₁-C₆heteroalkyl, $-C_1-C_6$ saturated alkyl-aryl, aryl, or heteroaryl;

each R₁₁ is independently halogen, nitro, $-OR_{10}$, $-N(R_{10})_2$, $-CN$, $-C(=O)R_{10}$, $-C(=O)OR_{10}$, $-C(=O)N(R_{10})_2$, $-NR_{10}C(=O)R_{10}$, $-NR_{10}SO_2R_{10}$, $-SOR_{10}$, $-SO_2R_{10}$, $-SO_2N(R_{10})_2$, $-C(=O)OCH_2SCH_3$, optionally substituted C₁-C₆ saturated alkyl, optionally substituted C₃-C₈cycloalkyl, optionally substituted C₁-C₆haloalkyl, optionally substituted C₁-C₆heteroalkyl, optionally substituted $-C_1-C_6$ alkyl-aryl, optionally substituted aryl, or optionally substituted heteroaryl; and

n is 0-2.

In another aspect, there is provided a pharmaceutical composition comprising a compound of any one of the Formulae described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Disclosed is a pharmaceutical composition comprising a compound of Formula I, IA, IB, II, IIA, IIB, III, IIIA, IIIB, IV, IVA, and IVB, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

5 In another aspect, there is provided use of a compound according to any one of the Formulae described herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a dermal disease, disorder or condition selected from skin aging, scarring, psoriasis, dermatitis, eczema, urticaria, rosacea, burns, and acne in a mammal.

10 Disclosed is a method of treating a disease, disorder or condition in a mammal that would benefit from LXR modulation comprising administering to the mammal a compound of Formula I, IA, IB, II, IIA, IIB, III, IIIA, IIIB, IV, IVA, and IVB, or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

15 In a further embodiment is a method of treating a disease, disorder or condition in a mammal that would benefit from LXR modulation comprising administering to the mammal a compound of Formula I, IA, IB, II, IIA, IIB, III, IIIA, IIIB, IV, IVA, and IVB, or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof; wherein the disease, disorder or condition in a mammal is a dermal disease, disorder or condition selected from skin aging, scarring, psoriasis, dermatitis, eczema, urticaria, rosacea, burns, and acne.

20 Disclosed is a method of modulating LXR activity comprising contacting LXR, or portion thereof, with a compound according to any one of the Formulae described herein, or a pharmaceutically acceptable salt thereof.

25 Disclosed is a method of modulating LXR activity comprising contacting LXR, or portion thereof, with a compound of Formula I, IA, IB, II, IIA, IIB, III, IIIA, IIIB, IV, IVA, and IVB, or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

INCORPORATION BY REFERENCE


30 All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

DETAILED DESCRIPTION OF THE INVENTION

35 LXR was first described by Willy, P. J., et al., "LXR, a nuclear receptor that defines a distinct retinoid response pathway," Genes & Development 9:1033-1045 (Cold Spring Harbor Laboratory Press).

WHAT IS CLAIMED IS:

1. A compound of Formula (III):




or a pharmaceutically acceptable salt thereof, wherein:

- L₁ is a bond;
- L₂ is a C₁-C₆saturated alkylene, or C₁-C₆heteroalkylene;
- R₁ is -C(=O)OR₈;
- R₂ is hydrogen, -OR₉, -N(R₉)₂, -C(=O)R₉, C₁-C₆saturated alkyl, C₃-C₈cycloalkyl, C₁-C₆haloalkyl, or optionally substituted heterocycloalkyl;
- R₃ is hydrogen, halogen, C₁-C₆saturated alkyl, or C₁-C₆haloalkyl;
- R₄ is aryl or heteroaryl; wherein aryl and heteroaryl are substituted with at least one R₁₁;
- each R₅ is independently halogen, C₁-C₆saturated alkyl, or C₁-C₆haloalkyl;
- R₈ is C₁-C₆saturated alkyl, C₁-C₆heteroalkyl, -C₁-C₆saturated alkyl-aryl, aryl, or heteroaryl;
- R₉ is hydrogen, C₁-C₆saturated alkyl, C₁-C₆heteroalkyl, -C₁-C₆saturated alkyl-aryl, aryl, or heteroaryl;
- each R₁₀ are each independently hydrogen, C₁-C₆saturated alkyl, C₁-C₆heteroalkyl, -C₁-C₆saturated alkyl-aryl, aryl, or heteroaryl;
- each R₁₁ is independently halogen, nitro, -OR₁₀, -N(R₁₀)₂, -CN, -C(=O)R₁₀, -C(=O)OR₁₀, -C(=O)N(R₁₀)₂, -NR₁₀C(=O)R₁₀, -NR₁₀SO₂R₁₀, -SOR₁₀, -SO₂R₁₀, -SO₂N(R₁₀)₂, -C(=O)OCH₂SCH₃, optionally substituted C₁-C₆saturated alkyl, optionally substituted C₃-C₈cycloalkyl, optionally substituted C₁-C₆haloalkyl, optionally substituted C₁-C₆heteroalkyl, optionally

substituted -C₁-C₆saturated alkyl-aryl, optionally substituted aryl, or optionally substituted heteroaryl; and

n is 0-4.

2. The compound of claim 1, wherein the compound is a compound of Formula (IIIA):




wherein:

m is 0 or 1; and

R_{11a} is -NR₁₀SO₂R₁₀, -SOR₁₀, -SO₂R₁₀, or -SO₂N(R₁₀)₂;

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1, wherein the compound is a compound of Formula (IIIB):



wherein m is 0 or 1;

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

L₁ is a bond;


R₁ is -C(=O)OR₈;

R₈ is C₁-C₆saturated alkyl;


L_2 is a C_1 - C_6 saturated alkylene;
 R_2 is hydrogen;
 R_4 is phenyl substituted with at least one R_{11} ;
each R_{11} is independently C_1 - C_6 saturated alkyl, $-NR_{10}SO_2R_{10}$, $-SOR_{10}$, $-SO_2R_{10}$, or $-SO_2N(R_{10})_2$; wherein said C_1 - C_6 saturated alkyl is optionally substituted by 1 hydroxy;
provided that at least one R_{11} is $-NR_{10}SO_2R_{10}$, $-SOR_{10}$, $-SO_2R_{10}$, or $-SO_2N(R_{10})_2$;
each R_{10} is independently C_1 - C_6 saturated alkyl;
 n is 0; and
 R_3 is hydrogen.

5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
- L_1 is a bond;
 R_1 is $-C(=O)OR_8$;
 R_8 is C_1 - C_6 saturated alkyl.
 L_2 is a C_1 - C_6 saturated alkylene;
 R_2 is hydrogen;
 R_4 is phenyl substituted with at least one R_{11} ;
each R_{11} is independently C_1 - C_6 saturated alkyl, $-NR_{10}SO_2R_{10}$, $-SOR_{10}$, $-SO_2R_{10}$, or $-SO_2N(R_{10})_2$; wherein said C_1 - C_6 saturated alkyl is optionally substituted by 1 hydroxy;
provided that at least one R_{11} is $-SO_2N(R_{10})_2$;
each R_{10} is independently C_1 - C_6 saturated alkyl;
 n is 0; and
 R_3 is hydrogen.

6. The compound of claim 1, selected from:




and



or a pharmaceutically acceptable salt thereof.

7. A compound of Formula (IV):



wherein:

R₁ is C₁-C₆ saturated alkyl or C₂-C₆ alkenyl, wherein said C₁-C₆ saturated alkyl is optionally substituted by 1, 2, 3, or 4 substituents independently selected from hydroxy, C₁-C₄ alkoxy, and C₁-C₄ haloalkoxy;

L₂ is a C₁-C₆ saturated alkylene;

R₂ is C(=O)OR₉;

R₃ is hydrogen or C₁-C₆ saturated alkyl;

R₄ is phenyl substituted with at least one R₁₁;


each R₉ is independently C₁-C₆ saturated alkyl;

each R₁₀ is independently hydrogen or C₁-C₆ saturated alkyl; and

each R₁₁ is independently halogen, nitro, -OR₁₀, -N(R₁₀)₂, -CN, -C(=O)R₁₀, -C(=O)OR₁₀, -C(=O)N(R₁₀)₂, -NR₁₀C(=O)R₁₀, -NR₁₀SO₂R₁₀, -SOR₁₀, -SO₂R₁₀, -SO₂N(R₁₀)₂, -C(=O)OCH₂CH₃, C₁-C₆ saturated alkyl, or C₁-C₆ halosaturated alkyl, wherein said C₁-C₆ saturated alkyl is optionally substituted by 1, 2, 3, or 4 substituents independently selected from cyano, hydroxy, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, amino, C₁-C₄ saturated alkylamino, and di(C₁-C₄ saturated alkyl)amino;

provided that at least one R₁₁ is -NR₁₀C(=O)R₁₀, -NR₁₀SO₂R₁₀, -SOR₁₀, -SO₂R₁₀, or -SO₂N(R₁₀)₂.

8. The compound of claim 7, wherein the compound is a compound of Formula (IVA):




wherein:

m is 0 or 1; and

R_{11a} is -NR₁₀SO₂R₁₀, -SOR₁₀, -SO₂R₁₀, or -SO₂N(R₁₀)₂;

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 7, wherein the compound is a compound of Formula (IVB):



wherein m is 0 or 1;

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 7, or a pharmaceutically acceptable salt thereof, wherein:

R₁ is C₂-C₄ alkenyl or C₁-C₃ saturated alkyl, wherein said C₁-C₃ saturated alkyl is optionally substituted by 1 hydroxy;


-L₂-R₂ is -CH₂C(=O)OR₉;

R₉ is C₁-C₆ saturated alkyl;

R₄ is phenyl substituted with at least one R₁₁;


each R_{11} is independently C_1 - C_6 saturated alkyl, $-NR_{10}SO_2R_{10}$, $-SOR_{10}$, $-SO_2R_{10}$, or $-SO_2N(R_{10})_2$; wherein said C_1 - C_6 saturated alkyl is optionally substituted by 1 hydroxy;
provided that at least one R_{11} is $-SO_2N(R_{10})_2$;
each R_{10} is independently C_1 - C_6 saturated alkyl; and
 R_3 is hydrogen.

11. The compound of claim 7, selected from:



or a pharmaceutically acceptable salt thereof.

12. A compound of Formula (IA):



wherein:

L_1 and L_2 are each independently a bond, C_1 - C_6 saturated alkylene, or C_1 - C_6 heteroalkylene; wherein C_1 - C_6 saturated alkylene and C_1 - C_6 heteroalkylene are optionally substituted with at least one R_7 ;

R_1 is halogen, $-CF_3$, $-OR_8$, $-N(R_8)_2$, $-C(=O)R_8$, $-C(=O)OR_8$, $-C(=O)N(R_8)_2$, $-C(=N-OH)R_8$, $-C(=S)N(R_8)_2$, C_1 - C_6 saturated alkyl, C_1 - C_6 heteroalkyl, or optionally substituted C_2 - C_7 heterocycloalkyl;

R_2 is $-C(=O)OR_9$;

R_3 is hydrogen, halogen, C_1 - C_6 saturated alkyl, or C_1 - C_6 haloalkyl;

each R_7 is independently C_1 - C_6 saturated alkyl, C_3 - C_8 cycloalkyl, C_1 - C_6 haloalkyl, C_1 - C_6 heteroalkyl, $-C_1$ - C_6 saturated alkyl-aryl, optionally substituted aryl, or optionally substituted heteroaryl;

each R_9 is independently C_1 - C_6 saturated alkyl, C_1 - C_6 heteroalkyl, $-C_1$ - C_6 saturated alkyl-aryl, aryl, or heteroaryl;

each R_8 and each R_{10} are each independently hydrogen, C_1 - C_6 saturated alkyl, C_1 - C_6 heteroalkyl, $-C_1$ - C_6 saturated alkyl-aryl, aryl, or heteroaryl;


m is 0 or 1;

R_{11a} is $-NR_{10}SO_2R_{10}$, $-SOR_{10}$, $-SO_2R_{10}$, or $-SO_2N(R_{10})_2$;

each R_{11} is independently halogen, nitro, $-OR_{10}$, $-N(R_{10})_2$, $-CN$, $-C(=O)R_{10}$, $-C(=O)OR_{10}$, $-C(=O)N(R_{10})_2$, $-NR_{10}C(=O)R_{10}$, $-NR_{10}SO_2R_{10}$, $-SOR_{10}$, $-SO_2R_{10}$, $-SO_2N(R_{10})_2$, $-C(=O)OCH_2SCH_3$, optionally substituted C_1 - C_6 saturated alkyl, optionally substituted C_3 - C_8 cycloalkyl, optionally substituted C_1 - C_6 haloalkyl, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted $-C_1$ - C_6 saturated alkyl-aryl, optionally substituted aryl, or optionally substituted heteroaryl;

or a pharmaceutically acceptable salt thereof.

13. The compound of claim 12, wherein the compound is a compound of Formula (IB):



wherein m is 0 or 1;

or a pharmaceutically acceptable salt thereof.

14. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein:

L_2 is C_1 - C_6 saturated alkylene;

R_2 is $-C(=O)OR_9$;

R_9 is C_1 - C_6 saturated alkyl;

L_1 is a bond; and R_1 is C_1 - C_6 saturated alkyl or $-CF_3$; or

L_1 is C_1 - C_6 saturated alkylene; and R_1 is $-OR_8$;

each R_{11} is independently C_1 - C_6 saturated alkyl or $-SO_2R_{10}$; wherein said C_1 - C_6 saturated alkyl is optionally substituted by 1 hydroxy;






provided that at least one R_{11} is $-SO_2R_{10}$;

each R_{10} is independently C_1 - C_6 saturated alkyl;

n is 0; and


R_3 is hydrogen,

15. The compound of claim 12, selected from:



or a pharmaceutically acceptable salt thereof.

16. A compound of Formula (II):



or a pharmaceutically acceptable salt thereof, wherein:

X is $-C(R_6)=C(R_6)-$;

L₁ is a bond, C₁-C₆saturated alkylene, or C₁-C₆heteroalkylene; wherein C₁-C₆saturated alkylene and C₁-C₆heteroalkylene are optionally substituted with at least one R₇;

L₂ is a C₁-C₆saturated alkylene or C₁-C₆heteroalkylene;

R₁ is -C(=O)OR₈;

R₂ is hydrogen, -OR₉, -N(R₉)₂, -C(=O)R₉, -C(=O)N(R₉)₂, -C(=N-OH)R₉, -C(=S)N(R₉)₂, C₁-C₆saturated alkyl, C₃-C₈cycloalkyl, C₁-C₆haloalkyl, C₁-C₆heteroalkyl, or optionally substituted heterocycloalkyl;

R₃ is hydrogen, halogen, C₁-C₆saturated alkyl, or C₁-C₆haloalkyl;

R₄ is aryl or heteroaryl; wherein aryl and heteroaryl are substituted with at least one R₁₁;

each R₅ is independently halogen, C₁-C₆saturated alkyl, or C₁-C₆haloalkyl;

each R₆ is independently hydrogen, halogen, C₁-C₆saturated alkyl, or C₁-C₆haloalkyl;

each R₇ is independently C₁-C₆saturated alkyl, C₃-C₈cycloalkyl, C₁-C₆haloalkyl, C₁-C₆heteroalkyl, -C₁-C₆saturated alkyl-aryl, optionally substituted aryl, or optionally substituted heteroaryl;


each R₈ is independently C₁-C₆saturated alkyl, C₁-C₆heteroalkyl, -C₁-C₆ saturated alkyl-aryl, aryl, or heteroaryl;

each R₉ and each R₁₀ are each independently hydrogen, C₁-C₆saturated alkyl, C₁-C₆heteroalkyl, -C₁-C₆saturated alkyl-aryl, aryl, or heteroaryl;

each R₁₁ is independently halogen, nitro, -OR₁₀, -N(R₁₀)₂, -CN, -C(=O)R₁₀, -C(=O)OR₁₀, -C(=O)N(R₁₀)₂, -NR₁₀C(=O)R₁₀, -NR₁₀SO₂R₁₀, -SOR₁₀, -SO₂R₁₀, -SO₂N(R₁₀)₂, -C(=O)OCH₂SCH₃, optionally substituted C₁-C₆saturated alkyl, optionally substituted C₃-C₈cycloalkyl, optionally substituted C₁-C₆haloalkyl, optionally substituted C₁-C₆heteroalkyl, optionally substituted -C₁-C₆alkyl-aryl, optionally substituted aryl, or optionally substituted heteroaryl; and

n is 0-2.


17. The compound of claim 16, wherein the compound is a compound of Formula (IIB):




wherein m is 0 or 1;
or a pharmaceutically acceptable salt thereof.

18. The compound of claim 17, or a pharmaceutically acceptable salt thereof, wherein:
 X is $-\text{CH}=\text{CH}-$;
 R_1 is a $-\text{C}(=\text{O})\text{OR}_8$; and R_8 is $\text{C}_1\text{-C}_6$ saturated alkyl;
 L_2 is $\text{C}_1\text{-C}_6$ saturated alkylene;
 R_2 is hydrogen;
 R_4 is phenyl substituted with at least one R_{11} ;
each R_{11} is independently $\text{C}_1\text{-C}_6$ saturated alkyl or $-\text{SO}_2\text{R}_{10}$; wherein said $\text{C}_1\text{-C}_6$ saturated alkyl is optionally substituted by 1 hydroxy;
provided that at least one R_{11} is $-\text{SO}_2\text{R}_{10}$;
each R_{10} is independently $\text{C}_1\text{-C}_6$ saturated alkyl;
 n is 0; and
 R_3 is hydrogen.

19. The compound of claim 16, selected from:



and



or a pharmaceutically acceptable salt thereof.

20. A pharmaceutical composition comprising a compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

21. Use of a compound according to any one of claims 1-19, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a dermal disease, disorder or condition selected from skin aging, scarring, psoriasis, dermatitis, eczema, urticaria, rosacea, burns, and acne in a mammal.